Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov 14;19(42):7302-7.
doi: 10.3748/wjg.v19.i42.7302.

Pharmacological challenges in chronic pancreatitis

Affiliations
Review

Pharmacological challenges in chronic pancreatitis

Anne Estrup Olesen et al. World J Gastroenterol. .

Abstract

Drug absorption in patients with chronic pancreatitis might be affected by the pathophysiology of the disease. The exocrine pancreatic insufficiency is associated with changes in gastrointestinal intraluminal pH, motility disorder, bacterial overgrowth and changed pancreatic gland secretion. Together these factors can result in malabsorption and may also affect the efficacy of pharmacological intervention. The lifestyle of chronic pancreatitis patients may also contribute to gastrointestinal changes. Many patients limit their food intake because of the pain caused by eating and in some cases food intake is more or less substituted with alcohol, tobacco and coffee. Alcohol and drug interaction are known to influence the pharmacokinetics by altering either drug absorption or by affecting liver metabolism. Since patients suffering from chronic pancreatitis experience severe pain, opioids are often prescribed as pain treatment. Opioids have intrinsic effects on gastrointestinal motility and hence can modify the absorption of other drugs taken at the same time. Furthermore, the increased fluid absorption caused by opioids will decrease water available for drug dissolution and may hereby affect absorption of the drug. As stated above many factors can influence drug absorption and metabolism in patients with chronic pancreatitis. The factors may not have clinical relevance, but may explain inter-individual variations in responses to a given drug, in patients with chronic pancreatitis.

Keywords: Absorption; Chronic pancreatitis; Metabolism; Pharmacology; Treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Absorption of pregabalin in eight female patients with chronic pancreatitis. Curves illustrate the variance in absorption of pregabalin after 75 mg pregabalin (oral capsule). Especially one patient varied from other subjects by having increased plasma concentration of pregabalin. Not a single cause could explain this outlier, but it could be a combination of several factors suggested.

References

    1. Chen JM, Férec C. Genetics and pathogenesis of chronic pancreatitis: the 2012 update. Clin Res Hepatol Gastroenterol. 2012;36:334–340. - PubMed
    1. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252–1261. - PMC - PubMed
    1. Hammer HF. Pancreatic exocrine insufficiency: diagnostic evaluation and replacement therapy with pancreatic enzymes. Dig Dis. 2010;28:339–343. - PubMed
    1. Pezzilli R. Chronic pancreatitis: maldigestion, intestinal ecology and intestinal inflammation. World J Gastroenterol. 2009;15:1673–1676. - PMC - PubMed
    1. Forsmark CE. Chronic pancreatitis and malabsorption. Am J Gastroenterol. 2004;99:1355–1357. - PubMed

Publication types

MeSH terms

Substances